Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer

被引：0

作者：

Shigeki Nanjo

Akito Hata

Chiyuki Okuda

Reiko Kaji

Hideaki Okada

Daisuke Tamura

Kei Irie

Hiroshi Okada

Shoji Fukushima

Nobuyuki Katakami

机构：

[1] Institute of Biomedical Research and Innovation Hospital,Division of Integrated Oncology

[2] 2-2,Department of Medical Oncology

[3] Minatojima-minamimachi,Department of Respiratory Medicine

[4] Chuo-ku,Department of Pharmacology

[5] Kobe 650-0047,Department of Pharmaceutics

[6] Japan,undefined

[7] Kobe Minimally Invasive Cancer Center,undefined

[8] Kobe 650-0046,undefined

[9] Japan,undefined

[10] Kobe University Hospital,undefined

[11] Kobe 650-0017,undefined

[12] Japan,undefined

[13] Institute of Biomedical Research and Innovation Hospital,undefined

[14] Kobe 650-0047,undefined

[15] Japan,undefined

[16] Faculty of Pharmaceutical Science,undefined

[17] Kobe Gakuin University,undefined

[18] Kobe 650-8586,undefined

[19] Japan,undefined

来源：

British Journal of Cancer | 2018年 / 118卷

关键词：

osimertinib; leptomeningeal metastases; T790M; cerebrospinal fluid;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：32 / 37

页数：5

共 50 条

[21] Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer [J].

Caressa Hui ;

Vera Qu ;

Jen-Yeu Wang ;

Rie von Eyben ;

Yu-Cheng Chang ;

Po-Lin Chiang ;

Chih-Hung Liang ;

Jen-Tang Lu ;

Gordon Li ;

Melanie Hayden-Gephart ;

Heather Wakelee ;

Joel Neal ;

Kavitha Ramchandran ;

Millie Das ;

Seema Nagpal ;

Scott Soltys ;

Nathaniel Myall ;

Erqi Pollom .

Journal of Neuro-Oncology, 2022, 160 :233-240

[22] Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer [J].

Hui, Caressa ;

Qu, Vera ;

Wang, Jen-Yeu ;

von Eyben, Rie ;

Chang, Yu-Cheng ;

Chiang, Po-Lin ;

Liang, Chih-Hung ;

Lu, Jen-Tang ;

Li, Gordon ;

Hayden-Gephart, Melanie ;

Wakelee, Heather ;

Neal, Joel ;

Ramchandran, Kavitha ;

Das, Millie ;

Nagpal, Seema ;

Soltys, Scott ;

Myall, Nathaniel ;

Pollom, Erqi .

JOURNAL OF NEURO-ONCOLOGY, 2022, 160 (01) :233-240

[23] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer [J].

Ortega-Franco, Ana ;

Rafee, Shereen .

ONCOLOGY AND THERAPY, 2022, 10 (01) :13-22

[24] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer [J].

Ana Ortega-Franco ;

Shereen Rafee .

Oncology and Therapy, 2022, 10 :13-22

[25] Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI [J].

Kim, Hye Ryeon ;

Jo, Hyunji ;

Kim, Hongsik ;

Hong, Joohyun ;

Park, Sehhoon ;

Jung, Hyun Ae ;

Lee, Se-Hoon ;

Ahn, Jin-Seok ;

Ahn, Myung-Ju .

CANCER RESEARCH AND TREATMENT, 2023, 55 (01) :344-349

[26] ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition [J].

Liu, Kejun ;

Chen, Xianwen ;

Wu, Ligang ;

Chen, Shiyuan ;

Fang, Nianxin ;

Cai, Limin ;

Jia, Jun .

BMC PULMONARY MEDICINE, 2021, 21 (01)

[27] Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer [J].

Tozuka, Takehiro ;

Noro, Rintaro ;

Mizutani, Hideaki ;

Kurimoto, Futoshi ;

Hakozaki, Taiki ;

Hisakane, Kakeru ;

Naito, Tomoyuki ;

Takahashi, Satoshi ;

Taniuchi, Namiko ;

Yajima, Chika ;

Hosomi, Yukio ;

Hirose, Takashi ;

Minegishi, Yuji ;

Okano, Tetsuya ;

Kamio, Koichiro ;

Yamaguchi, Tomoyoshi ;

Seike, Masahiro .

LUNG CANCER, 2024, 191

[28] EGFR-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing [J].

Sukari, Ammar ;

Nagasaka, Misako ;

Wakeling, Erin .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (10) :1188-1192

[29] Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma [J].

Liu, Yang ;

Xiong, Zhi-Cheng ;

Sun, Xin ;

Sun, Li ;

Zhang, Shu-Ling ;

Ma, Jie-Tao ;

Han, Cheng-Bo .

TRANSLATIONAL CANCER RESEARCH, 2019, 8 (05) :2151-2163

[30] Efficacy and Safety of Osimertinib as Third-Line or Later Therapy for T790M-Positive Advanced Non-Small Cell Lung Cancer [J].

Shimada, H. ;

Endo, S. ;

Sasahara, Y. ;

Shinmura, T. ;

Ozawa, T. ;

Majima, H. ;

Hara, T. ;

Imase, R. ;

Yamauchi, S. ;

Sakakibara, Y. ;

Kobayashi, A. ;

Yamazaki, K. ;

Jin, Y. ;

Yamanaka, K. ;

Matsubara, O. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S2138-S2139

← 1 2 3 4 5 →